New combination improves outcomes for small cell bladder and neuroendocrine prostate cancer patients: early stage but clinical study
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2: Food as Medicine Research from City Of Hope
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxAnother Potential Breakthrough: 3-in-1 Antibody Shows Promise
/0 Comments/in Immunotherapy, Not PCa related, Preclinical Research/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/0 Comments/in Observational, Post-hoc, Retrospective studies/by MaxAn add-on strategy to maximize workouts: electro stimulation works for cancer patients
/0 Comments/in Clinical Trial, Metastatic/by MaxHopefully a Breakthrough: CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy
/1 Comment/in Immunotherapy, Not PCa related, Preclinical Research/by MaxUnlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxAnother AlphaFold evolution: Using AI to Identify Better Antibody Therapies
/0 Comments/in Artificial Intelligence, Not PCa related/by MaxAlphaFold keeps rocking: a new AI tool that can predict large proteins
/0 Comments/in Artificial Intelligence/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment cancer vaccine clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide hormone therapy immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology neuroendocrine prostate cancer oncology oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy targeted drug delivery theranostics
Latest Posts
- Predictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients April 16, 2025
- Phase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer April 15, 2025
- Newsletter 15/2025 April 13, 2025
- Phase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT April 11, 2025